What is the MyDRUG study?
[cm_tooltip_parse]MyDRUG is a bold and ambitious clinical cancer research study that builds upon our previous innovations and discoveries. When we developed the largest comprehensive genomic landscape through our CoMMpass Study, we discovered that multiple myeloma is not just one disease — it has many different subtypes defined by specific genetic mutations. Through the MyDRUG clinical trial, we are testing drugs designed specifically for each subtype, greatly improving the odds of accelerating treatments that will help each and every patient.
Unlike traditional clinical trials, which test one drug or a single combination of drugs, the MyDRUG clinical trial tests the impact of several different drugs on different genetic mutations. This not only quickens the speed by which new treatments are tested but also more efficiently matches patients to treatments that are most likely to be beneficial.
The MyDRUG clinical trial is enrolling patients at cancer centers and academic research institutions throughout the United States that are part of the MMRF’s research collaborative, the Multiple Myeloma Research Consortium (MMRC).[/cm_tooltip_parse]
Patient Navigation Center
[cm_tooltip_parse]Talk to a myeloma expert at our Patient Navigation Center to further understand your diagnosis, get answers to your critical questions, and receive guidance on the best treatment option for you. [/cm_tooltip_parse]
Give us a call Monday–Friday, 9 AM-7 PM ET 1-888-841-MMRF(6673)
MyDRUG clinical trial patient FAQs
- Received at least one but no more than three prior therapies
- Relapsed within 12-18 months of starting their second-line treatment or were refractory to their initial treatment
Based on their unique genetic makeup, patients enrolled in the MyDRUG clinical trial are assigned to a particular treatment known to precisely target the mutations in their cancer. This kind of clinical trial is sometimes called a platform trial. By testing multiple different treatments, platform trials are able to more quickly determine whether a treatment is effective and more efficiently identify individuals and small groups of patients who will reap the most benefit from the new treatment.
MyDRUG clinical trial health care provider FAQs
Each patient who is eligible and consents to participate in MyDRUG will receive genomic screening. A sample from their bone marrow biopsy will be sent to the University of Michigan for genomic analysis. Based on the results, the patient will be assigned to receive therapy on one of several treatment arms.
There are six treatment arms in MyDRUG. Five are based on previously identified actionable mutations in multiple myeloma and test an investigational therapy that targets a specific mutation. Patients found not to have any actionable mutations will receive the standard of care triplet regimen of ixazomib, pomalidomide and dexamethasone. Each treatment arm will enroll up to 38 patients.
MyDRUG is a type of platform study that is designed with the flexibility to open and close treatment arms. This innovative study design not only has the potential to hasten the speed by which new treatments are tested but also more efficiently matches patients to treatments that are most likely to be beneficial.